drugset / Trial / NCT02247414

Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection

NCT02247414

Phase 4 Completed 124 enrolled Yangzhou University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Warfarin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension

Timeline

Start
2014-09
Primary completion
2017-09
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 100 mg Oral
Subject Warfarin Small molecule 2.5 mg Oral
Background Dipyridamole Other / unclassified 25 mg Oral
Background Heparin Other / unclassified 4100 iu Subcutaneous